| 1. |
- Polettini, M., et al.
(författare)
-
Decay studies in the A∼225 Po-Fr region from the DESPEC campaign at GSI in 2021
- 2022
-
Ingår i: Il Nuovo Cimento. - : Società Italiana di Fisica. - 2037-4909. ; 45:5
-
Tidskriftsartikel (refereegranskat)abstract
- The HISPEC-DESPEC collaboration aims at investigating the structure of exotic nuclei formed in fragmentation reactions with decay spectroscopy measurements, as part of the FAIR Phase-0 campaign at GSI. This paper reports on first results of an experiment performed in spring 2021, with a focus on beta-decaystudies in the Po-Fr nuclei in the 220 < A <230 island of octupole deformation exploiting the DESPEC setup. Ion-beta correlations and fast-timing techniques are being employed, giving an insight into this difficult-to-reach region.
|
|
| 2. |
- Batista, N, et al.
(författare)
-
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
- 2004
-
Ingår i: Br J Cancer. - 0007-0920. ; 90:9, s. 1740-6
-
Tidskriftsartikel (refereegranskat)abstract
- The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC). This phase II study evaluates the efficacy and safety of a 21-day cycle of oral capecitabine (1000 mg m(-2) twice daily, days 1-14) plus i.v. paclitaxel (175 mg m(-2), day 1) in anthracycline-pretreated advanced/MBC. In all, 73 patients were enrolled at 13 Swedish and Spanish centres. The objective response rate was 52% (95% confidence interval (CI): 40-63%) in the intent-to-treat population, including complete responses in 11%. Disease was stabilised in a further 29%. The median time to disease progression (TTP) was 8.1 months and the median overall survival was 16.5 months. The combination was generally well tolerated with a predictable safety profile. The most common treatment-related nonhaematological adverse events were hand-foot syndrome (42%), alopecia (30%) and diarrhoea (26%). The only treatment-related Grade 3/4 adverse events occurring in >5% of patients were alopecia (22%) and hand-foot syndrome (11%). Grade 3/4 neutropenia and lymphocytopenia were reported in 12 and 14% of patients, respectively. Capecitabine plus paclitaxel is highly active with a favourable safety profile in anthracycline-pretreated MBC.
|
|
| 3. |
- Lehoux, A. P., et al.
(författare)
-
Transport and Adsorption of Nano-Colloids in Porous Media Observed by Magnetic Resonance Imaging
- 2017
-
Ingår i: Transport in Porous Media. - : Springer. - 0169-3913 .- 1573-1634. ; 119:2, s. 403-423
-
Tidskriftsartikel (refereegranskat)abstract
- We use magnetic resonance imaging to follow the adsorption of colloids during their transport through a porous medium (grain packing). We injected successive pulses of a suspension of nanoparticles able to adsorb onto the grains. To get quantitative information we carry out 2D imaging and 1D measurements of the evolution in time of the distribution profile of all particles (suspended or adsorbed) in cross-sectional layers along the sample axis during the flow. For the first injections we observe the 1D profile amplitude progressively damping as particles advance through the sample, due to their adsorption. 2D imaging shows that successive injections finally result in a coverage of grains by adsorbed particles regularly progressing along the sample. The analysis of the results makes it possible to get a clear description of the adsorption process. In our specific case (particle charged oppositely to the adsorption sites) it appears that the particles rapidly explore the pores and adsorb as soon as they encounter available sites on grains, and the surplus of particles goes on advancing in the sample. A further analysis of the profiles makes it possible to distinguish the respective concentration distribution of suspended and adsorbed particles over time at each step of the process.
|
|
| 4. |
|
|
